ULTRAGENYX PHARMACEUTICAL INC. Other Noncash Income (Expense)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Other Noncash Income (Expense) of $4.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for the quarter ending 2026-06-30 was $5.00M.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$1.00M, a 200.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$693.00K.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for the quarter ending 2025-09-30 was $1.69M, a 59.46% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for fiscal 2025 was $2.00M, a 0.00% change from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for fiscal 2024 was $2.00M.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for fiscal 2023 was -$3.00M, a 1404.35% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. other noncash income (expense) for fiscal 2022 was $230.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.00M 10-Q · filed 2026-08-05 | $3.31M derived: sum of 3 quarters · filed 2026-08-05 | $5.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$1.00M 10-Q · filed 2026-05-06 | -$1.69M derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.00M derived: sum of 2 quarters · filed 2026-02-18 | $1.00M derived: sum of 3 quarters · filed 2026-08-05 | $2.00M 10-K · filed 2026-02-18 | ||||
| 2025-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.69M derived: sum of 2 quarters · filed 2026-08-05 | $2.69M 10-Q · filed 2025-11-05 | $14.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.00M 10-Q · filed 2026-08-05 | $2.42M 10-Q · filed 2025-08-06 | -$1.68M derived: sum of 3 quarters · filed 2026-08-05 | $2.50M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-06 | $1.25M 10-Q · filed 2025-05-07 | -$1.68M derived: sum of 2 quarters · filed 2026-05-06 | $2.50M derived: sum of 3 quarters · filed 2026-05-06 | $2.92M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.50M derived: sum of 2 quarters · filed 2026-02-18 | $1.92M derived: sum of 3 quarters · filed 2026-02-18 | $2.00M 10-K · filed 2026-02-18 | $3.49M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.60M derived: sum of 2 quarters · filed 2025-11-05 | $4.68M 10-Q · filed 2025-11-05 | $4.25M 10-Q · filed 2024-11-06 | $4.78M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-30 | $426.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $503.00K 10-Q · filed 2025-08-06 | $748.00K 10-Q · filed 2024-08-02 | $605.00K derived: sum of 3 quarters · filed 2026-02-18 | -$442.00K derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-31 | $77.00K 10-Q · filed 2025-05-07 | $179.00K derived: sum of 2 quarters · filed 2026-02-18 | -$868.00K derived: sum of 3 quarters · filed 2026-02-18 | -$2.74M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2023-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$945.00K derived: sum of 2 quarters · filed 2026-02-18 | -$2.81M derived: sum of 3 quarters · filed 2026-02-18 | -$3.00M 10-K · filed 2026-02-18 | -$2.30M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$2.92M derived: sum of 2 quarters · filed 2024-11-06 | -$3.10M 10-Q · filed 2024-11-06 | -$2.31M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$2.06M 10-Q · filed 2024-08-02 | -$1.26M derived: sum of 3 quarters · filed 2025-02-19 | -$1.44M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | -$187.00K 10-Q · filed 2024-05-03 | $607.00K derived: sum of 2 quarters · filed 2025-02-19 | $429.00K derived: sum of 3 quarters · filed 2025-02-19 | $78.00K derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $794.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $616.00K derived: sum of 2 quarters · filed 2025-02-19 | $265.00K derived: sum of 3 quarters · filed 2025-02-19 | $230.00K 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$529.00K derived: sum of 2 quarters · filed 2023-11-03 | -$564.00K 10-Q · filed 2023-11-03 | -$366.00K derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | -$351.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$386.00K 10-Q · filed 2023-08-04 | -$188.00K derived: sum of 3 quarters · filed 2024-02-21 | -$110.00K derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$35.00K 10-Q · filed 2023-05-05 | $163.00K derived: sum of 2 quarters · filed 2024-02-21 | $241.00K derived: sum of 3 quarters · filed 2024-02-21 | $55.00K derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $276.00K derived: sum of 2 quarters · filed 2024-02-21 | $90.00K derived: sum of 3 quarters · filed 2024-02-21 | -$235.00K 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $78.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$108.00K derived: sum of 2 quarters · filed 2022-11-03 | -$433.00K 10-Q · filed 2022-11-03 | -$901.00K derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | -$186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$511.00K 10-Q · filed 2022-07-29 | -$979.00K derived: sum of 3 quarters · filed 2023-02-17 | -$1.47M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | -$325.00K 10-Q · filed 2022-05-06 | -$793.00K derived: sum of 2 quarters · filed 2023-02-17 | -$1.28M derived: sum of 3 quarters · filed 2023-02-17 | -$808.00K derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | -$468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$960.00K derived: sum of 2 quarters · filed 2023-02-17 | -$483.00K derived: sum of 3 quarters · filed 2023-02-17 | -$946.00K 10-K · filed 2023-02-17 | -$1.17M 10-K · filed 2021-02-12 | |||
| 2020-09-30 | -$492.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$15.00K derived: sum of 2 quarters · filed 2021-11-03 | -$478.00K 10-Q · filed 2021-11-03 | $28.00K 10-Q · filed 2020-10-27 | -$2.88M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-06-30 | $477.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $14.00K 10-Q · filed 2021-08-03 | -$34.00K 10-Q · filed 2020-07-30 | -$2.39M derived: sum of 3 quarters · filed 2022-02-15 | -$2.74M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-03-31 | -$463.00K 10-Q · filed 2021-05-05 | -$2.86M derived: sum of 2 quarters · filed 2022-02-15 | -$3.22M derived: sum of 3 quarters · filed 2022-02-15 | |||||
| 2019-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$2.75M derived: sum of 2 quarters · filed 2022-02-15 | -$2.62M 10-K · filed 2022-02-15 | -$557.00K 10-K · filed 2020-02-14 | ||||
| 2019-09-30 | -$352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | -$220.00K 10-Q · filed 2020-10-27 | ||||||
| 2019-06-30 | $132.00K 10-Q · filed 2020-07-30 | |||||||
| 2018-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $11.00K derived: sum of 2 quarters · filed 2021-02-12 | $156.00K 10-K · filed 2021-02-12 | |||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $145.00K 10-Q · filed 2019-11-06 | ||||||
| 2018-06-30 | $145.00K 10-Q · filed 2019-08-02 | |||||||
| 2016-12-31 | -$700.00K 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |